PDS Biotechnology (NASDAQ:PDSB) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research report report published on Friday.

Several other equities research analysts also recently commented on PDSB. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $14.25.

PDS Biotechnology Stock Up 0.9 %

Shares of NASDAQ:PDSB opened at $3.23 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. PDS Biotechnology has a 52-week low of $2.53 and a 52-week high of $6.85. The business’s 50 day simple moving average is $3.24 and its two-hundred day simple moving average is $3.28. The firm has a market cap of $118.93 million, a P/E ratio of -2.65 and a beta of 1.93.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company posted ($0.37) earnings per share. As a group, research analysts forecast that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors have recently added to or reduced their stakes in PDSB. Vanguard Group Inc. boosted its stake in shares of PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares during the last quarter. Inspirion Wealth Advisors LLC lifted its holdings in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after acquiring an additional 4,917 shares during the period. Blair William & Co. IL boosted its position in PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at $146,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $120,000. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.